跳至主要内容
临床试验/CTRI/2025/06/088752
CTRI/2025/06/088752尚未招募3 期

A clinical study to evaluate the efficacy of bilvadi gutika in blood eosinophilia

Dr Raghavendra Swamy P1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2025年6月23日最近更新:

试验速览

阶段
3 期
状态
尚未招募
发起方
入组人数
30
试验地点
1
主要终点
Reduce in absolute eosinophil counts

研究概览

简要总结

this clinical study is about intervention of an ayurvedic formulation called bilvadi gutika in allergic conditions as per the ayurvedic classical reference in order to check the reduce in absolute eosinophil count in the cases of blood eosinophilia. the aim is to study the effect of bilvadi gutika in blood eosinophilia. it is a single arm clinical study with minimum of 30 subjects fulfilling the diagnostic and inclusion criteria, such as the subject with a history of any allergy since 1 year, diagnosis cases of allergy, raised total eosinophil count and raised absolute eosinophil count. subjects will be included between 16 to 60 years of age irrespective of gender. the subject will be administered bilvadi gutika in the dosage of 500mg 2 tablets thrice daily with hot water for 4 weeks. post trial follow up period is 4 weeks. total duration of study is 8 weeks.  the observation will be done initially on 1st day before the treatment after 28th day and after 56th day. the effect of treatment will be assessed on the basis of gradation for both subjective and objective parameter before and after the treatment.

研究设计

研究类型
Interventional
分配方式
Na
盲法
None

入排标准

年龄范围
16.00 Year(s) 至 60.00 Year(s)(—)
性别
All

入选标准

  • patient suffering from allergic asthma, allergic cough and allergic skin manifestation since 1 year.
  • diagnosed cases of allergy with not more than 1 year.
  • raised total and absolute eosinophil counts.
  • patient with who have taken anthelminthic drugs at least 3-4 months before.

排除标准

  • patient suffering from psychological disorders, pregnant and lactating women.
  • patient suffering from other systemic diseases or other skin diseases that interfere in prognosis and treatment of disease.
  • patient suffering from fatal diseases like carcinoma of lungs and immunocompromised cases.

结局指标

主要结局

Reduce in absolute eosinophil counts

时间窗: Reduce in absolute eosinophil counts

次要结局

  • reduction in subjective parameter.(reduction in symptoms & signs)

研究者

发起方
Dr Raghavendra Swamy P
申办方类型
Other [self ]
责任方
Principal Investigator
主要研究者

Dr Raghavendra Swamy P

Alvas ayurveda medical collage and hospital

研究点 (1)

Loading locations...

相似试验